Adenocarcinoma of the Extrahepatic Biliary Tree

 

Epidemiology:

    • 60s and 70s
      • younger when associated with PSC
    • Risk factors:
      • PSC
      • UC
      • Cystic liver diseases (Caroli disease, choledochal cysts)
      • Gallstones (debateable)
      • Infections:
        • Biliary tree fluke infections (Clonorchis sinensis) in Asia
        • Salmonella typhi (chronic)

 

Common sites:

    • Upper third (majority)
      • proximal to the cystic duct junction, including both hepatic ducts, CBD, and cystic duct
    • Klatskin tumour – arises between cystic duct junction and the confluence of the right and left hepatic ducts

 

Gross features:

    • small (usually symptomatic)
    • Firm, grey nodules within the bile duct wall
    • 4 “types” described with significant overlap
      • polypoid type:
        • papillary
        • friable
        • soft
        • tan
      • nodular type:
        • infiltrating pattern usually
      • scirrhous constricting type:
        • infiltrating pattern usually
      • diffusely infiltrating type:
        • spreads linearly along ducts
    • spread to regional lymph nodes, distant sites (30-70%), or diffuse peritoneal seeding in later stages

 

Histologic features:

    • most are pancreatobiliary type adenocarcinomas (similar to gallbladder carcinoma)
      • may be mucin-secreting or not
      • other types include intestinal, squamous/adenosquamous, small cell, signet ring cell, mucinous, and undifferentiated carcinomas
    • abundant fibrous stroma usually
    • perineural invasion often (not seen in benign conditions)
    • may be deceptively benign-appearing
      • nuclear atypia is not important for diagnosis
      • conversely, reactive atypia may be malignant-appearing
    • haphazard distribution of glands
    • wider, more open luminae than benign glands
    • irregular or angular contours of glands may be present
    • loss of polarity may be present
    • grading (same as rest of GI tract):
      • grade 1 – well differentiated - > 95% glands
      • grade 2 – moderately differentiated – 50-95% glands
      • grade 3 – poorly differentiated - < 50% glands
    • papillary adenocarcinoma:
      • papillary architecture
      • well-differentiated
      • good prognosis
    • intestinal type
    • gastric foveolar type
    • mucinous adenocarcinoma
    • Clear cell adenocarcinoma:
      • Similar to gallbladder variant
    • Signet-ring cell carcinoma
    • Foamy-gland variant:
      • Similar to gallbladder variant
      • Prominent nuclear polarity
      • Distinctive microvesicular (foamy) cytoplasm
      • Chromophilic condensation of apical cytoplasm
      • Nuclei may be slightly irregular shape
        • Grooves may be present
        • Prominent nucleoli not helpful
    • Lobular variant:
      • Similar to gallbladder variant
    • Prognostic parameters similar to gallbladder
    • squamous features uncommonly
    • Middle third (upper half of CBD) carcinomas:
      • Perineural invasion particularly frequent
    •  

 

Immunophenotype:

Marker:

Sensitivity:

Specificity:

MUC1

MUC5AC

(cytoplasmic)

(apical membrane staining is normal)

“almost all”

Differentiate from intestinal-type adenoCA

P53 

>50%

 

CEA (cytoplasmic)

(apical membrane staining is normal)

 

 

    •  endocrine cells often demonstrable

 

Molecular features:

    • mutations in codon 12 of k-ras oncogene
    • loss of DPC4 (distal > proximal)

 

Other features:

    • poor prognosis (mean survival 6-18mo.)
      • usually not surgically respectable despite small size
        • distal third (lower half of CBD) are most respectable (Whipple) and have best prognosis
    • Well-differentiated (usually polypoid/papillary) have best prognosis
    • Klatskin:
      • slow-growing
      • relatively infrequent distal metastases
    • better prognosis elevated CEA and CA19-9
    • familial syndromes:
      • FAP (cases reported)
      • Type 1 neurofibromatosis (rarely)
    • Clinical features:
      • Cholestasis
      • Acanthosis nigricans
    • 5% have synchronous gallbladder carcinoma

 

References:

    • Robbins 2005
    • Sternberg 2004